{"id":"NCT00483704","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Multiple Attacks Study to Compare the Efficacy and Safety of MK-0974 With Placebo for Acute Migraine (MK-0974-031)","officialTitle":"A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Multiple Attacks Study to Compare the Efficacy and Safety of Oral MK-0974 With Placebo for the Acute Treatment of Migraine With or Without Aura","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-08-14","primaryCompletion":"2009-03-25","completion":"2009-03-25","firstPosted":"2007-06-07","resultsPosted":"2014-08-29","lastUpdate":"2018-10-18"},"enrollment":1935,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Migraines"],"interventions":[{"type":"DRUG","name":"Telcagepant 140 mg","otherNames":[]},{"type":"DRUG","name":"Talcagepant 280 mg","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Telcagepant 140 mg","type":"EXPERIMENTAL"},{"label":"Telcagepant 280 mg","type":"EXPERIMENTAL"},{"label":"Control Group 1","type":"PLACEBO_COMPARATOR"},{"label":"Control Group 2","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to assess the safety and efficacy of telcagepant (MK-0974) in acute treatment of multiple migraine attacks with or without aura. Primary hypotheses of this study are that telcagepant is superior to placebo, as measured by the proportion of participants who have pain freedom, pain relief, pain freedom consistency, pain relief consistency, and absence of photophobia, phonophobia, and nausea at 2 hours post-dose.","primaryOutcome":{"measure":"Percentage of Participants Reporting Pain Freedom at 2 Hours Post-dose (First Migraine Attack)","timeFrame":"2 hours post-dose for the first migraine attack (up to 6 months)","effectByArm":[{"arm":"Telcagepant 140 mg","deltaMin":21.9,"sd":null},{"arm":"Telcagepant 280 mg","deltaMin":25.1,"sd":null},{"arm":"Placebo","deltaMin":10.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG001 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["20974601"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":573},"commonTop":["Dry mouth","Nausea","Dizziness","Fatigue","Somnolence"]}}